Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Inclusion Criteria:

Patients will have measurable disseminated colorectal cancer that is incurable by surgery
Patients will have had tumor progression following standard combination front-line or second-line chemotherapy.
CRC patients who have relapsed or recurrent disease within six months after completing adjuvant or neoadjuvant chemotherapy

Exclusion Criteria:

Previous treatment with PARP inhibitors, including olaparib.
Patients with symptomatic, uncontrolled brain metastases.
Patients receiving any chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study entry (or a longer period depending on the defined characteristics of the agents used).
Patients who are unable to swallow orally administered medication.